INmune Bio (INMB) Competitors $2.71 -0.07 (-2.52%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$3.42 +0.71 (+26.20%) As of 07/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMB vs. OGI, SLS, YMAB, ALMS, CTMX, SXTC, VYGR, KYTX, GNFT, and DRUGShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Organigram Global (OGI), SELLAS Life Sciences Group (SLS), Y-mAbs Therapeutics (YMAB), Alumis (ALMS), CytomX Therapeutics (CTMX), China SXT Pharmaceuticals (SXTC), Voyager Therapeutics (VYGR), Kyverna Therapeutics (KYTX), GENFIT (GNFT), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. INmune Bio vs. Its Competitors Organigram Global SELLAS Life Sciences Group Y-mAbs Therapeutics Alumis CytomX Therapeutics China SXT Pharmaceuticals Voyager Therapeutics Kyverna Therapeutics GENFIT Bright Minds Biosciences INmune Bio (NASDAQ:INMB) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership. Which has more risk & volatility, INMB or OGI? INmune Bio has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Organigram Global has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Which has better earnings and valuation, INMB or OGI? Organigram Global has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$50K1,278.31-$42.08M-$1.93-1.40Organigram Global$117.47M1.74-$33.39M$0.1015.30 Does the media prefer INMB or OGI? In the previous week, INmune Bio had 1 more articles in the media than Organigram Global. MarketBeat recorded 2 mentions for INmune Bio and 1 mentions for Organigram Global. Organigram Global's average media sentiment score of 1.87 beat INmune Bio's score of 1.08 indicating that Organigram Global is being referred to more favorably in the news media. Company Overall Sentiment INmune Bio Positive Organigram Global Very Positive Do analysts recommend INMB or OGI? INmune Bio presently has a consensus target price of $18.40, suggesting a potential upside of 578.97%. Given INmune Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe INmune Bio is more favorable than Organigram Global.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57Organigram Global 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is INMB or OGI more profitable? Organigram Global has a net margin of 8.05% compared to INmune Bio's net margin of 0.00%. Organigram Global's return on equity of -5.93% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets INmune BioN/A -119.35% -89.37% Organigram Global 8.05%-5.93%-4.39% Do institutionals and insiders have more ownership in INMB or OGI? 12.7% of INmune Bio shares are held by institutional investors. Comparatively, 34.6% of Organigram Global shares are held by institutional investors. 35.7% of INmune Bio shares are held by company insiders. Comparatively, 0.1% of Organigram Global shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryOrganigram Global beats INmune Bio on 10 of the 17 factors compared between the two stocks. Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.57M$3.05B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.00%P/E Ratio-1.4021.3228.3920.08Price / Sales1,278.31285.38431.7689.31Price / CashN/A42.7636.2258.56Price / Book1.878.378.675.88Net Income-$42.08M-$55.19M$3.25B$258.89M7 Day Performance11.98%5.86%4.25%3.71%1 Month Performance-56.85%17.29%10.51%11.72%1 Year Performance-68.41%4.39%35.68%18.01% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio1.9968 of 5 stars$2.71-2.5%$18.40+579.0%-68.0%$65.57M$50K-1.4010Positive NewsUpcoming EarningsOGIOrganigram Global1.3149 of 5 stars$1.48+2.1%N/A-5.6%$198.23M$117.47M14.80860Positive NewsSLSSELLAS Life Sciences Group2.323 of 5 stars$1.98+7.6%N/A+55.2%$197.56M$1M-5.2110YMABY-mAbs Therapeutics3.6508 of 5 stars$4.36flat$15.60+257.8%-61.3%$197.42M$87.68M-6.81150News CoveragePositive NewsALMSAlumis3.2443 of 5 stars$3.60+2.3%$22.86+534.9%-69.8%$195.88MN/A0.00N/ANews CoverageAnalyst ForecastGap UpCTMXCytomX Therapeutics4.196 of 5 stars$2.39-1.2%$5.33+123.2%+69.0%$192.68M$138.10M4.98170News CoveragePositive NewsGap UpSXTCChina SXT Pharmaceuticals1.2221 of 5 stars$1.66-5.1%N/A-82.5%$192.61M$1.93M0.0090Gap UpVYGRVoyager Therapeutics3.9067 of 5 stars$3.43-1.7%$13.39+290.4%-64.7%$189.82M$80M-2.35100KYTXKyverna Therapeutics2.7026 of 5 stars$4.39+8.9%$18.50+321.4%-51.3%$189.74M$7.03M-1.3096Positive NewsGNFTGENFIT2.4804 of 5 stars$3.79+3.8%$13.00+243.0%-10.1%$189.50M$76.77M0.00120Positive NewsGap UpDRUGBright Minds Biosciences2.443 of 5 stars$25.65+3.4%$83.25+224.6%+2,830.6%$180.68MN/A-71.25N/ANews CoveragePositive News Related Companies and Tools Related Companies Organigram Global Competitors SELLAS Life Sciences Group Competitors Y-mAbs Therapeutics Competitors Alumis Competitors CytomX Therapeutics Competitors China SXT Pharmaceuticals Competitors Voyager Therapeutics Competitors Kyverna Therapeutics Competitors GENFIT Competitors Bright Minds Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMB) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INMB Stock Alerts